Literature DB >> 2843558

Human parvovirus B19: ELISA and immunoblot assays.

T F Schwarz1, M Roggendorf, F Deinhardt.   

Abstract

An ELISA for the detection of specific IgM and IgG against human parvovirus B19 (anti-B19 IgM and IgG) and B19 antigen is described. With ELISA anti-B19 IgM could be detected for up to 20 weeks after viraemia. Four to five months after B19 infection anti-B19 IgG titres range between 10(-6) and 10(-7). Nonspecific reactions with rheumatoid factor or IgM against rubella were not found. The ELISA for B19 antigen was shown to be as sensitive as DNA hybridisation. With immunoblotting two viral proteins of 83 kd (VP1) and 58 kd (VP2) were demonstrated. After acute infection antibodies to VP2 appear before antibodies to VP1. Immunoblotting might be used in pregnancy to determine the time of maternal infection. In a survey of a B19 outbreak in a school for medical technology, 6 (28.6%) of 21 non-immune females seroconverted.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843558     DOI: 10.1016/0166-0934(88)90149-8

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  22 in total

1.  Parvovirus diagnostics and vaccine production in insect cells.

Authors:  J I Casal
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

2.  New oligopeptide immunoglobulin G test for human parvovirus B19 antibodies.

Authors:  T F Schwarz; S Modrow; B Hottenträger; B Höflacher; G Jäger; W Scharti; R Sumazakl; H Wolf; J Middeldorp; M Roggendorf
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

3.  Acute parvovirus B19 infection mimicking myelodysplastic syndrome of the bone marrow.

Authors:  H Baurmann; T F Schwarz; J Oertel; S Serke; M Roggendorf; D Huhn
Journal:  Ann Hematol       Date:  1992-01       Impact factor: 3.673

4.  Subunit interaction in B19 parvovirus empty capsids.

Authors:  S J Rosenfeld; N S Young; D Alling; J Ayub; C Saxinger
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

5.  Human parvovirus B19 infection associated with vascular purpura and vasculitis.

Authors:  T F Schwarz; R Bruns; C Schröder; S Wiersbitzky; M Roggendorf
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

6.  Evaluation of four commercial enzyme immunoassays for detection of immunoglobulin M antibodies to human parvovirus B19.

Authors:  T Sloots; P L Devine
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-09       Impact factor: 3.267

7.  Immune response to B19 parvovirus and an antibody defect in persistent viral infection.

Authors:  G J Kurtzman; B J Cohen; A M Field; R Oseas; R M Blaese; N S Young
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

8.  Evaluation of five commercial tests for detection of immunoglobulin M antibodies to human parvovirus B19.

Authors:  A L Bruu; S A Nordbø
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

9.  Use of recombinant human parvovirus B19 antigens in serological assays.

Authors:  H A Cubie; E E Leslie; S Smith; H J O'Neill; H Hart; B J Cohen; J M Inglis
Journal:  J Clin Pathol       Date:  1993-09       Impact factor: 3.411

10.  Effects of human parvovirus B19 VP1 unique region protein on macrophage responses.

Authors:  Bor-Show Tzang; Chun-Ching Chiu; Chun-Chou Tsai; Yi-Ju Lee; I-Jung Lu; Jing-Yu Shi; Tsai-Ching Hsu
Journal:  J Biomed Sci       Date:  2009-01-24       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.